Loss of G-protein-signaling modulator 2 accelerates proliferation of lung adenocarcinoma via EGFR signaling pathway

Mingming Deng(Chinese Academy of Medical Sciences & Peking Union Medical College), Xuejun Hu(Zoucheng People's Hospital), Xiaofang Che(First Hospital of China Medical University), Yang Chen(Chinese Academy of Sciences), Ye Zhang(University of Electronic Science and Technology of China), Yizhe Wang(First Hospital of China Medical University), Ximing Wang(Shandong University), Qingjie Lv(China Medical University), Zhe Zhang(Sun Yat-sen University), Xianghong Yang(China Medical University), Kezuo Hou(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Bofang Liu(First Hospital of China Medical University)
The International Journal of Biochemistry & Cell Biology
February 11, 2020
10.1016/j.biocel.2020.105716
Cited by 27

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417